Recent Updates
Recently added Catalysts
STOK Positive Sentiment

Stoke Therapeutics Announces Third Quarter 2026 Financial Results and Provides Business Updates

Thursday, October 29, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Stoke Therapeutics reported third-quarter 2026 financial results and provided business updates. The company highlighted progress on its lead candidate, zorevunersen, for Dravet syndrome. This RNA medicine aims to restore protein expression as a first-in-class treatment. The announcement covered operational developments through September 30, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • Stoke Therapeutics reported financial results for Q3 2026.
  • The company is advancing its lead investigational medicine, zorevunersen.
  • Zorevunersen is a potential disease-modifying treatment for Dravet syndrome.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
6.8%
average across 5 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
zorevunersen
Phase 3 · Dravet Syndrome

Full Press Release Details

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today reported financial results for the third quarter ended September 30, 2026, and provided business updates including progress of the global

Frequently Asked Questions

What financial results did Stoke Therapeutics announce?

Stoke Therapeutics reported its financial results for the third quarter of 2026.

What is zorevunersen?

Zorevunersen is an investigational medicine for Dravet syndrome.

What is the focus of Stoke Therapeutics?

The company focuses on restoring protein expression using RNA medicine.

What condition is zorevunersen targeting?

Zorevunersen targets Dravet syndrome as a potential disease-modifying treatment.

ShareAdd on Google
Tags: STOK Stoke Therapeutics zorevunersen Dravet syndrome financial results biotechnology
Last updated: Oct 29, 2026

Biotech snapshot

Cash runway
$354M liquidity · $19M/mo burn
~16 mo
Low dilution risk
Lead asset
zorevunersenPhase 3
Dravet Syndrome →

Catalyst track record

+11%
best trade around STOK's most recent catalyst

Peak hindsight return over a 120-day window, across 5 tracked FDA/PDUFA catalysts for STOK.

See every catalyst's timing & PoA →